Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDentaIDTA -14.29%50 Cyclically Adjusted PB Ratio is 3.26 as of Sep. 17, 2026. GuruFocus rates IDTA with a GF Score™ of 50/100 and a GF Value™ of $0.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 127 Medical Diagnostics & Research companies, IDenta ranks worse than 787400.79% on this metric.
IDenta does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
Shiller PE for Stocks: The True Measure of Stock Valuation
IDenta (OTCPK:IDTA) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
IDenta Cyclically Adjusted PB Ratio Related Terms
IDenta Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for IDenta's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDTA vs FUNI, IVRO, NSTM: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, IDenta's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDenta Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDenta's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where IDenta's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
IDenta does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
What does a Cyclically Adjusted PB Ratio of 3.26 mean?
IDenta (IDTA) has a Cyclically Adjusted PB Ratio of 3.26 as of Sep. 17, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on IDenta and its competitors. According to the industry distribution chart, IDenta ranks #999999 out of 127 companies in the Medical Diagnostics & Research industry.
Is IDenta's Cyclically Adjusted PB Ratio too high?
IDenta's current Cyclically Adjusted PB Ratio is 3.26. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.72. IDenta's value of 3.26 is 89.5% above this industry median. Based on the distribution chart, IDenta ranks #999999 out of 127 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDenta has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDenta's Cyclically Adjusted PB Ratio compare to FUNI and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, IDenta ranks #999999 out of 127 companies for Cyclically Adjusted PB Ratio. This places IDenta in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.72. IDenta's value of 3.26 is 89.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.72, based on 127 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDenta's current Cyclically Adjusted PB Ratio of 3.26 is 89.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on IDenta and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDenta's current Cyclically Adjusted PB Ratio is 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDenta stock overvalued right now?
Based on GuruFocus' analysis, IDenta (IDTA) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.36, compared to a current price of $0.30 — trading 16.7% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 3.26 and 89.5% above the Medical Diagnostics & Research industry median of 1.72. IDenta's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For IDenta (IDTA), the current Cyclically Adjusted PB Ratio is 3.26 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDenta (IDTA) Overvalued in 2026?
Based on GuruFocus' analysis, IDenta stock appears to be undervalued.
The current stock price of $0.30 is trading 16.7% below its estimated GF Value™ of $0.36.
GuruFocus considers IDenta to be Modestly Undervalued.
Key valuation signals for IDTA:
Cyclically Adjusted PB Ratio: 3.26
GF Value™: $0.36 vs. price of $0.30 (16.7% below fair value)
Industry Position: 89.5% above the Medical Diagnostics & Research median (#999999 of 127)
No single metric tells the full story. See the IDTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDenta Corp is a detection and forensic science company. The firm, through its subsidiary, is engaged in the business of developing products to test for the presence of illegal drugs and explosives for law enforcement agencies, ports and border crossings, shipping hubs, and other organizations. Its product portfolio includes Drug testing kits, Explosive testing kits, Forensic products, Urine drug testing and others. The company currently sells its products to law enforcement organizations in the following countries: Indonesia, Argentina, Poland, France, USA, Spain, India, the United Kingdom, Ghana, Nigeria, Australia, Russia, Israel, Canada, Germany, Italy, and Portugal. The company also sells to retail markets in the United States, Italy, and South Africa.
50GF Score
Get the complete analysis for IDTA
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDTA has been successfully added to your 
